In comparison to the monoclonal antibody checkpoint inhibitor that disrupts the programmed cell death 1 (PD-1)/PD-1 ligand 1 (PD-L1) axis, UMCD6 exhibits greater efficacy in inducing cancer cell death and decreasing the survival rate of cancer cells in vitro12. The gene discussed is PDCD1; the disease is cancer.